Does the media favor BEAM or DNLI?

In the previous week, Denali Therapeutics had 2 more articles in the media than Beam Therapeutics. MarketBeat recorded 7 mentions for Denali Therapeutics and 5 mentions for Beam Therapeutics. Denali Therapeutics' average media sentiment score of 1.32 beat Beam Therapeutics' score of 1.17 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DNLI or ASND?

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 7 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.32 beat Ascendis Pharma A/S's score of 1.04 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BMRN or DNLI?

In the previous week, BioMarin Pharmaceutical had 27 more articles in the media than Denali Therapeutics. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 7 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.32 beat BioMarin Pharmaceutical's score of 0.73 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 13 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, DNLI or EXEL?

Exelixis has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Denali Therapeutics $330.53M 12.05 -$512.54M -$2.84 N/A Exelixis $2.32B 5.78 $782.57M $3.18 17.01

Does the media favor DNLI or EXEL?

In the previous week, Exelixis had 9 more articles in the media than Denali Therapeutics. MarketBeat recorded 16 mentions for Exelixis and 7 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.32 beat Exelixis' score of 1.18 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 11 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DNLI or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Denali Therapeutics. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 7 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.32 beat Arrowhead Pharmaceuticals' score of 0.90 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Denali Therapeutics (DNLI) Competitors

$24.92 -0.03 (-0.12%)

As of 08/21/2026 04:00 PM Eastern

Compare

DNLI vs. BEAM, ASND, BMRN, EXEL, and ARWR

Should you buy Denali Therapeutics stock or one of its competitors? Denali Therapeutics's main competitors and comparable companies include Beam Therapeutics (BEAM), Ascendis Pharma A/S (ASND), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), and Arrowhead Pharmaceuticals (ARWR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Denali Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Beam Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

Beam Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	22.00	-$79.99M	-$0.86	N/A
Denali Therapeutics	$330.53M	12.05	-$512.54M	-$2.84	N/A

In the previous week, Denali Therapeutics had 2 more articles in the media than Beam Therapeutics. MarketBeat recorded 7 mentions for Denali Therapeutics and 5 mentions for Beam Therapeutics. Denali Therapeutics' average media sentiment score of 1.32 beat Beam Therapeutics' score of 1.17 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -54.75%. Beam Therapeutics' return on equity of -30.71% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Denali Therapeutics	N/A	-55.27%	-44.24%

Beam Therapeutics currently has a consensus price target of $49.00, indicating a potential upside of 64.65%. Denali Therapeutics has a consensus price target of $35.92, indicating a potential upside of 44.13%. Given Beam Therapeutics' higher probable upside, equities analysts plainly believe Beam Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Beam Therapeutics and Denali Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to Ascendis Pharma A/S?

Denali Therapeutics (NASDAQ:DNLI) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Denali Therapeutics has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

Denali Therapeutics currently has a consensus price target of $35.92, indicating a potential upside of 44.13%. Ascendis Pharma A/S has a consensus price target of $300.33, indicating a potential upside of 18.57%. Given Denali Therapeutics' higher possible upside, equities research analysts clearly believe Denali Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 7 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.32 beat Ascendis Pharma A/S's score of 1.04 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	12.05	-$512.54M	-$2.84	N/A
Ascendis Pharma A/S	$1.05B	15.09	-$258M	$12.89	19.65

Ascendis Pharma A/S has a net margin of 70.99% compared to Denali Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

92.9% of Denali Therapeutics shares are owned by institutional investors. 9.7% of Denali Therapeutics shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Ascendis Pharma A/S beats Denali Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Denali Therapeutics compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

BioMarin Pharmaceutical currently has a consensus price target of $88.83, indicating a potential upside of 33.17%. Denali Therapeutics has a consensus price target of $35.92, indicating a potential upside of 44.13%. Given Denali Therapeutics' higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

BioMarin Pharmaceutical has a net margin of 2.14% compared to Denali Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Denali Therapeutics	N/A	-55.27%	-44.24%

BioMarin Pharmaceutical has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	4.01	$348.90M	$0.37	180.27
Denali Therapeutics	$330.53M	12.05	-$512.54M	-$2.84	N/A

BioMarin Pharmaceutical has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

In the previous week, BioMarin Pharmaceutical had 27 more articles in the media than Denali Therapeutics. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 7 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.32 beat BioMarin Pharmaceutical's score of 0.73 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	13 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioMarin Pharmaceutical beats Denali Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to Exelixis?

Denali Therapeutics (NASDAQ:DNLI) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Denali Therapeutics has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 9.7% of Denali Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Exelixis has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	12.05	-$512.54M	-$2.84	N/A
Exelixis	$2.32B	5.78	$782.57M	$3.18	17.01

Denali Therapeutics currently has a consensus target price of $35.92, indicating a potential upside of 44.13%. Exelixis has a consensus target price of $50.07, indicating a potential downside of 7.42%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Denali Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30

Exelixis has a net margin of 35.33% compared to Denali Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Exelixis	35.33%	42.17%	31.76%

In the previous week, Exelixis had 9 more articles in the media than Denali Therapeutics. MarketBeat recorded 16 mentions for Exelixis and 7 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.32 beat Exelixis' score of 1.18 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	11 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Exelixis beats Denali Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Denali Therapeutics compare to Arrowhead Pharmaceuticals?

Denali Therapeutics (NASDAQ:DNLI) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Denali Therapeutics presently has a consensus target price of $35.92, indicating a potential upside of 44.13%. Arrowhead Pharmaceuticals has a consensus target price of $97.33, indicating a potential upside of 11.74%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Denali Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Arrowhead Pharmaceuticals has higher revenue and earnings than Denali Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	12.05	-$512.54M	-$2.84	N/A
Arrowhead Pharmaceuticals	$829.45M	14.79	-$1.63M	-$2.25	N/A

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Denali Therapeutics. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 7 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.32 beat Arrowhead Pharmaceuticals' score of 0.90 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Denali Therapeutics' return on equity of -55.27% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

Denali Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 9.7% of Denali Therapeutics shares are held by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Denali Therapeutics beats Arrowhead Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Denali Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNLI vs. The Competition

Export

Metric	Denali Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.98B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-8.77	11.62	272.60	24.24
Price / Sales	12.05	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	4.77	16.80	13.05	6.20
Net Income	-$512.54M	-$12.50M	$3.47B	$348.59M
7 Day Performance	2.13%	3.29%	2.09%	0.08%
1 Month Performance	6.40%	8.23%	6.64%	3.88%
1 Year Performance	60.88%	55.05%	25.02%	16.98%

Denali Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNLI Denali Therapeutics	3.3975 of 5 stars	$24.92 -0.1%	$35.92 +44.1%	+60.9%	$3.98B	$330.53M	N/A	430	News Coverage Positive News
BEAM Beam Therapeutics	2.1691 of 5 stars	$27.10 +1.3%	$49.00 +80.8%	+78.8%	$2.76B	$139.74M	N/A	510	Positive News
ASND Ascendis Pharma A/S	4.6109 of 5 stars	$247.40 -0.4%	$299.24 +21.0%	+30.4%	$15.50B	$814.57M	19.19	1,189	Earnings Report Analyst Forecast Insider Trade
BMRN BioMarin Pharmaceutical	4.8149 of 5 stars	$66.64 -1.1%	$88.45 +32.7%	+13.9%	$13.04B	$3.41B	180.11	3,221	Analyst Forecast
EXEL Exelixis	3.3916 of 5 stars	$52.32 +2.1%	$49.79 -4.8%	+40.0%	$12.70B	$2.32B	16.45	1,077	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DNLI) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Denali Therapeutics (DNLI) Competitors

DNLI vs. BEAM, ASND, BMRN, EXEL, and ARWR

How does Denali Therapeutics compare to Beam Therapeutics?

Summary

How does Denali Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Denali Therapeutics compare to BioMarin Pharmaceutical?

Summary

How does Denali Therapeutics compare to Exelixis?

Summary

How does Denali Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI vs. The Competition

Denali Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Denali Therapeutics (DNLI) Competitors

DNLI vs. BEAM, ASND, BMRN, EXEL, and ARWR

How does Denali Therapeutics compare to Beam Therapeutics?

Do institutionals and insiders have more ownership in BEAM or DNLI?

Which has more volatility and risk, BEAM or DNLI?

Which has stronger valuation and earnings, BEAM or DNLI?

Does the media favor BEAM or DNLI?

Is BEAM or DNLI more profitable?

Do analysts prefer BEAM or DNLI?

Summary

How does Denali Therapeutics compare to Ascendis Pharma A/S?

Which has more volatility and risk, DNLI or ASND?

Do analysts rate DNLI or ASND?

Does the media prefer DNLI or ASND?

Which has higher earnings and valuation, DNLI or ASND?

Is DNLI or ASND more profitable?

Do insiders and institutionals believe in DNLI or ASND?

Summary

How does Denali Therapeutics compare to BioMarin Pharmaceutical?

Do insiders & institutionals believe in BMRN or DNLI?

Do analysts prefer BMRN or DNLI?

Is BMRN or DNLI more profitable?

Which has stronger earnings and valuation, BMRN or DNLI?

Which has more risk and volatility, BMRN or DNLI?

Does the media favor BMRN or DNLI?

Summary

How does Denali Therapeutics compare to Exelixis?

Which has more risk & volatility, DNLI or EXEL?

Do institutionals and insiders believe in DNLI or EXEL?

Which has higher valuation and earnings, DNLI or EXEL?

Do analysts prefer DNLI or EXEL?

Is DNLI or EXEL more profitable?

Does the media favor DNLI or EXEL?

Summary

How does Denali Therapeutics compare to Arrowhead Pharmaceuticals?

Do analysts rate DNLI or ARWR?

Which has preferable valuation & earnings, DNLI or ARWR?

Does the media favor DNLI or ARWR?

Is DNLI or ARWR more profitable?

Which has more volatility & risk, DNLI or ARWR?

Do institutionals & insiders hold more shares of DNLI or ARWR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI vs. The Competition

Denali Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools